Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MetaStatMTST EV-to-OCF is -0.00 as of Aug. 11, 2026.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, MetaStat's Enterprise Value is $0.01 Mil.
MetaStat's Cash Flow from Operations for the trailing twelve months (TTM) ended in Feb. 2018 was $-2.74 Mil. Therefore, MetaStat's EV-to-OCF for today is -0.00.
The historical rank and industry rank for MetaStat's EV-to-OCF or its related term are showing as below:
MTST's EV-to-OCF is not ranked *
in the Biotechnology industry.
Industry Median: -3.515 * Ranked among companies with meaningful EV-to-OCF only.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MetaStat's share price for today is $0.001.
MetaStat's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MetaStat EV-to-OCF Related Terms
MetaStat EV-to-OCF Historical Data
* Premium members only.
The historical data trend for MetaStat's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MetaStat's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MetaStat EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MetaStat's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where MetaStat's EV-to-OCF falls into.
MetaStat's current Enterprise Value is $0.01 Mil.
MetaStat's Cash Flow from Operations for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MetaStat (MTST) has a EV-to-OCF of -0.00 as of Aug. 11, 2026.
Is MetaStat's EV-to-OCF too high?
MetaStat's current EV-to-OCF is -0.00.
How does MetaStat's EV-to-OCF compare to OBMP and NSPX?
MetaStat's EV-to-OCF of -0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. MetaStat's current EV-to-OCF is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current EV-to-OCF of -0.00. The current EV-to-OCF is -0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For MetaStat (MTST), the current EV-to-OCF is -0.00 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MTST has been successfully added to your 
